AustinPx Introduces KinetiSol™ Equipment Leasing Program AustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally administered small molecule drugs, has announced the launch of its groundbreaking KinetiLease™ program. This initiative allows pharmaceutical companies to…
Unlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials Unlearn®, a leader in AI-powered solutions for clinical trials, has announced a strategic collaboration with Trace Neuroscience, a biotechnology company specializing in genomic therapies for neurodegenerative diseases. This partnership is…
Align Technology Launches Invisalign® With Mandibular Advancement for Class II Correction Align Technology, Inc. (Nasdaq: ALGN), a globally recognized medical device company specializing in digital orthodontics and restorative dentistry, has announced the commercial availability of its latest innovation: the Invisalign…
MANSCAPED Unveils TCS Ball Hero Bundle for Testicular Cancer Awareness MANSCAPED, the global leader in men’s grooming, has built a reputation not only for its innovative grooming products and clever marketing but also for its commitment to a cause that…
Devonian Announces Delay in Financial Results Release Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for inflammatory diseases, has announced a delay in filing its…
LucyRx Unveils Bold Brand Identity, Celebrates Key Milestones to Simplify PBM and Enhance Patient Care LucyRx, a next-generation pharmacy benefit manager (PBM), is shaking up the landscape of prescription care with its innovative approach, compassionate values, and impressive growth. With…
Omeros Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Omeros Corporation has announced its recent developments, clinical updates, and financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Clinical Developments: Other Developments: CEO’s…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in its efforts to expand cancer treatment options. The Committee for…
WuXi Biologics Achieves ISO 22301 Certification and Expands ISO/IEC 27001 Compliance WuXi Biologics (“WuXi Bio”) (2269.HK), a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a significant milestone in its ongoing commitment to operational resilience and information…
Ono & Reborna Partner for CNS RNA-Targeting Drug Discovery Ono Pharmaceutical Co., Ltd. (Headquartered in Osaka, Japan; President and COO: Toichi Takino; hereafter referred to as “Ono”) has announced a strategic collaboration agreement with Reborna Biosciences, Inc. (Headquartered in Kanagawa,…
Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant milestone in oncology treatment development, as Bristol Myers Squibb has received a positive opinion from the Committee for…
ACC 2025 Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company specializing in non-invasive cardiac assessment technologies, has announced promising results from a recent clinical study evaluating its AI-powered Cardiac Performance System (CPS™). These findings were…